Sphera Funds Management LTD. purchased a new stake in Urovant Sciences Ltd (NASDAQ:UROV) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 164,030 shares of the company’s stock, valued at approximately $1,968,000.

Several other hedge funds also recently modified their holdings of the stock. FMR LLC bought a new stake in shares of Urovant Sciences in the third quarter valued at approximately $14,400,000. BlackRock Inc. bought a new stake in shares of Urovant Sciences in the third quarter valued at approximately $4,574,000. Citadel Advisors LLC bought a new stake in shares of Urovant Sciences in the third quarter valued at approximately $2,209,000. Asymmetry Capital Management L.P. bought a new stake in shares of Urovant Sciences in the third quarter valued at approximately $1,902,000. Finally, Laurion Capital Management LP bought a new stake in shares of Urovant Sciences in the third quarter valued at approximately $1,200,000. Institutional investors and hedge funds own 23.12% of the company’s stock.

NASDAQ UROV opened at $6.80 on Friday. Urovant Sciences Ltd has a fifty-two week low of $6.65 and a fifty-two week high of $14.32.

Urovant Sciences (NASDAQ:UROV) last released its earnings results on Monday, November 12th. The company reported ($1.23) earnings per share for the quarter, missing the consensus estimate of ($0.93) by ($0.30). Equities analysts anticipate that Urovant Sciences Ltd will post -4.04 earnings per share for the current fiscal year.

In other Urovant Sciences news, major shareholder Fund V. Lp Qvt bought 2,678,571 shares of the business’s stock in a transaction on Monday, October 1st. The stock was purchased at an average cost of $14.00 per share, for a total transaction of $37,499,994.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Several brokerages recently issued reports on UROV. JPMorgan Chase & Co. began coverage on Urovant Sciences in a research note on Monday, October 22nd. They issued an “overweight” rating and a $21.00 price target for the company. Cowen started coverage on Urovant Sciences in a research note on Monday, October 22nd. They issued an “outperform” rating and a $25.00 price target for the company. Finally, Jefferies Financial Group started coverage on Urovant Sciences in a research note on Monday, October 22nd. They set a “buy” rating and a $19.00 target price for the company.

ILLEGAL ACTIVITY NOTICE: This story was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dailypolitical.com/2018/12/08/sphera-funds-management-ltd-purchases-shares-of-164030-urovant-sciences-ltd-urov.html.

Urovant Sciences Company Profile

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.

Recommended Story: The risks of owning bonds

Want to see what other hedge funds are holding UROV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Urovant Sciences Ltd (NASDAQ:UROV).

Institutional Ownership by Quarter for Urovant Sciences (NASDAQ:UROV)

Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.